| Product Code: ETC7181129 | Publication Date: Sep 2024 | Updated Date: Oct 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 | |
In 2024, Fiji continued to rely on key trading partners such as Australia, New Zealand, India, Bangladesh, and the USA for its neuroprotective agents imports. Despite a decline in growth rate from 2023 to 2024, the compound annual growth rate (CAGR) over the period 2020-24 remained strong at 6.89%. The high Herfindahl-Hirschman Index (HHI) indicates a concentrated market, emphasizing the dominance of these top exporting countries in supplying neuroprotective agents to Fiji. Continued collaboration and strategic partnerships with these countries may further drive growth and innovation in Fiji`s neuroprotective agents market.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Fiji Neuroprotective Agents Market Overview |
3.1 Fiji Country Macro Economic Indicators |
3.2 Fiji Neuroprotective Agents Market Revenues & Volume, 2021 & 2031F |
3.3 Fiji Neuroprotective Agents Market - Industry Life Cycle |
3.4 Fiji Neuroprotective Agents Market - Porter's Five Forces |
3.5 Fiji Neuroprotective Agents Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.6 Fiji Neuroprotective Agents Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.7 Fiji Neuroprotective Agents Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 Fiji Neuroprotective Agents Market Revenues & Volume Share, By Distribution Cahnnel, 2021 & 2031F |
4 Fiji Neuroprotective Agents Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Growing awareness about neurological disorders and the importance of neuroprotection. |
4.2.2 Increasing research and development activities in the field of neuroprotective agents. |
4.2.3 Rising geriatric population prone to neurological diseases in Fiji. |
4.3 Market Restraints |
4.3.1 Stringent regulations and approval processes for neuroprotective agents. |
4.3.2 High cost associated with the development and production of neuroprotective agents. |
5 Fiji Neuroprotective Agents Market Trends |
6 Fiji Neuroprotective Agents Market, By Types |
6.1 Fiji Neuroprotective Agents Market, By Drug Class |
6.1.1 Overview and Analysis |
6.1.2 Fiji Neuroprotective Agents Market Revenues & Volume, By Drug Class, 2021- 2031F |
6.1.3 Fiji Neuroprotective Agents Market Revenues & Volume, By Anesthetics, 2021- 2031F |
6.1.4 Fiji Neuroprotective Agents Market Revenues & Volume, By Antagonists, 2021- 2031F |
6.1.5 Fiji Neuroprotective Agents Market Revenues & Volume, By Antidepressants, 2021- 2031F |
6.1.6 Fiji Neuroprotective Agents Market Revenues & Volume, By Cytokines, 2021- 2031F |
6.1.7 Fiji Neuroprotective Agents Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Fiji Neuroprotective Agents Market, By Application |
6.2.1 Overview and Analysis |
6.2.2 Fiji Neuroprotective Agents Market Revenues & Volume, By Alzheimer's disease, 2021- 2031F |
6.2.3 Fiji Neuroprotective Agents Market Revenues & Volume, By Dementia, 2021- 2031F |
6.2.4 Fiji Neuroprotective Agents Market Revenues & Volume, By Epilepsy, 2021- 2031F |
6.2.5 Fiji Neuroprotective Agents Market Revenues & Volume, By Multiple sclerosis, 2021- 2031F |
6.2.6 Fiji Neuroprotective Agents Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Fiji Neuroprotective Agents Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 Fiji Neuroprotective Agents Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.3 Fiji Neuroprotective Agents Market Revenues & Volume, By Topical, 2021- 2031F |
6.3.4 Fiji Neuroprotective Agents Market Revenues & Volume, By Epidural, 2021- 2031F |
6.3.5 Fiji Neuroprotective Agents Market Revenues & Volume, By Intravenous, 2021- 2031F |
6.4 Fiji Neuroprotective Agents Market, By Distribution Cahnnel |
6.4.1 Overview and Analysis |
6.4.2 Fiji Neuroprotective Agents Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F |
6.4.3 Fiji Neuroprotective Agents Market Revenues & Volume, By Retail Pharmacies, 2021- 2031F |
6.4.4 Fiji Neuroprotective Agents Market Revenues & Volume, By Drug Stores, 2021- 2031F |
6.4.5 Fiji Neuroprotective Agents Market Revenues & Volume, By Online Pharmacies, 2021- 2031F |
7 Fiji Neuroprotective Agents Market Import-Export Trade Statistics |
7.1 Fiji Neuroprotective Agents Market Export to Major Countries |
7.2 Fiji Neuroprotective Agents Market Imports from Major Countries |
8 Fiji Neuroprotective Agents Market Key Performance Indicators |
8.1 Number of clinical trials for neuroprotective agents conducted in Fiji. |
8.2 Percentage of healthcare professionals recommending neuroprotective agents. |
8.3 Investment in neuroprotective agent research and development in Fiji. |
9 Fiji Neuroprotective Agents Market - Opportunity Assessment |
9.1 Fiji Neuroprotective Agents Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.2 Fiji Neuroprotective Agents Market Opportunity Assessment, By Application, 2021 & 2031F |
9.3 Fiji Neuroprotective Agents Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 Fiji Neuroprotective Agents Market Opportunity Assessment, By Distribution Cahnnel, 2021 & 2031F |
10 Fiji Neuroprotective Agents Market - Competitive Landscape |
10.1 Fiji Neuroprotective Agents Market Revenue Share, By Companies, 2024 |
10.2 Fiji Neuroprotective Agents Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |